Showing results (131-140 of 144) with videos related to
Sort By:
Pageof 15
JAMA Oncology|February 8, 2024
Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor-Related Bone Metastases: A Randomized, Double-Blind, Phase 3 Equivalence TrialShaohua Zhang, Yongmei Yin, Hailin Xiong, et al.The Lancet. Respiratory Medicine|October 20, 2019
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trialYunpeng Yang, Jianya Zhou, Jianying Zhou, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2021
Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA SequencingYunpeng Yang, Jie Huang, Tao Wang, et al.Cancer Communications (London, England)|February 29, 2024
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II studyJing Zheng, Tao Wang, Yunpeng Yang, et al.Cancer Communications (London, England)|April 2, 2026
Rezivertinib in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Central Nervous System Metastasis: Central Nervous System Efficacy from the Phase III REZOR StudySheng Yang, Yanqiu Zhao, Meili Sun, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational TrialShun Lu, Qiming Wang, Guojun Zhang, et al.Lung Cancer (Amsterdam, Netherlands)|August 1, 2024
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trialShun Lu, Yiping Zhang, Guojun Zhang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 20, 2022
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label StudyShun Lu, Yiping Zhang, Guojun Zhang, et al.The Lancet. Respiratory Medicine|February 6, 2025
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 studyYuankai Shi, Yanzhen Guo, Xingya Li, et al.Cancer Communications (London, England)|July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)Shun Lu, Xiaorong Dong, Hong Jian, et al.Pageof 15